ArticleJBMR plus2026
Risk factors for atypical femur fractures with and without bisphosphonate treatment: a national nested case-control study.
Article in JBMR plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atypical femur fractures (AFF) are rare stress fractures linked to long-term bisphosphonate (BP) use. However, since some patients develop AFF without BP exposure (BP-naïve), additional mechanisms have been proposed. In this study, we tested medication use, clinical characteristics, and femoral geometry. We started with a hypothesis that BP-naïve patients would have additional risk factors in these areas compared with BP-users. We included 172 patients aged ≥55 yr who sustained AFF in Sweden between 2008 and 2010. Among them, 134 had used BPs prior to the fracture and 38 had not. All fractures met the 2014 ASBMR major criteria for AFF. Data on medication use, comorbidities, and demographics were extracted from national registers, and radiographs were reviewed to assess femoral geometry. All statistical models were adjusted for sex and age. We found that among BP-naïve patients, male sex was more common (21.1%) than among BP-users (3.0%). Additionally, BP-naïve patients were less likely to use calcium supplementation (23.7% vs 90.3%, OR 0.04, 95% CI 0.01-0.10), corticosteroids (13.2% vs 35.8%, OR 0.18, 95% CI 0.05-0.52), proton pump inhibitors (23.7% vs 41.8%, OR 0.36, 95% CI 0.14-0.85), and beta-blockers (28.9% vs 47.0%, OR 0.43, 95% CI 0.18-0.97). Moreover, BP-naïve patients had fewer diagnosed bone disorders, including osteoporosis (5.3% vs 34.3%, OR 0.10, 95% CI 0.02-0.38). Bisphosphonate-naïve patients did have a higher lateral-to-medial cortical thickness ratio (1.00 vs 0.90,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.